Osteoarthritis
Conditions
Keywords
synovial fluid, biomarkers
Brief summary
Osteoarthritis is a condition that causes joints in the human body to deteriorate over time. This condition affects more than 250 million people around the globe. Currently, the goal of treating osteoarthritis involves reducing the severity and pain that results from the disease. The ultimate goal of this study is to identify patients with pre-arthritic joints (before symptoms or disease characteristics appear) in an effort to find and use treatments that stop or slow the disease. Joints are filled with a naturally occurring liquid known as synovial fluid. Molecules (biomarkers) and genetic expression of various cell types within synovial joint fluid may serve as measures of onset and progression of osteoarthritis. These samples have the potential to improve diagnosis, classification, and treatment, possibly changing the natural history of this debilitating disease. The purpose of this study is to develop a collection of synovial fluid samples from the shoulder, hip and knee for the analysis of biomarkers and cellular and genetic components therein to better understand the pre-arthritic joint, progression to disease, and response to interventions.
Interventions
PROCEDUREArthroscopy
Arthroscopic Surgery on the hip, shoulder, or knee
PROCEDUREArthroplasty
Total hip, shoulder, or knee arthroplasty
Sponsors
Duke University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult patients ( \> 18 years old) 2. Patient is eligible for general anesthesia and either arthroscopy or arthroplasty. 3. Patient needs standard of care arthroscopy or arthroplasty of either shoulder, hip or knee joint for osteoarthritis or prearthritic conditions. 4. Patient must have signed an IRB approved informed consent document for the arthrocentesis procedure which will be performed during the arthroscopic or arthroplastic procedure.
Exclusion criteria
1. Active Joint Infection within last 6 months. 2. Previous arthroplasty in the joint undergoing arthroplasty 3. History of auto-immune arthropathies. 4. History of HIV or Hepatitis C
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of biobank data collection as measured by percentage of patients with a complete data set one year post-operation | 1 year | Study participants will be enrolled over an anticipated time frame of 2 years. One year following the last participant's enrollment prompts an anticipated three year time frame to determine the feasibility of biobank data collection. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of biomarkers worthy of study to aid in the diagnosis and progression of osteoarthritis | 3-5 years | Biomarkers for study include the following: CRP, Eotaxin, Eotaxin-3, FGF (basic), Flt-1/VEGFR1, GM-CSF, ICAM-1, IFN-γ, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-8 (HA), IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, PlGF, SAA, TARC, Tie-2, TNF-α, TNF-β, VCAM-1, VEGF-A, VEGF-C, VEGF-D, clusterin, lubricin, and matrix molecules. |
| Types of biomarkers worthy of study to aid in the diagnosis and progression of osteoarthritis | 3-5 years | Types of biomarkers include the following: chemokines, cytokines, inflammatory, angiogenesis, and vascular injury. |
| Number of patients who responded to non-arthroplasty intervention based on biomarker analysis and measured with questionnaires | 1-10 years | — |
| Number of patients who did not respond to non-arthroplasty intervention based on biomarker analysis and measured with questionnaires | 1-10 years | — |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORRichard C. Mather, MD, MBA
Duke University
Outcome results
None listed